Tanios Bekaii-Saab, MD
A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer (mCRC), according to data from the phase II ReDOS trial now published in the Lancet Oncology
Bekaii-Saab TS, Ou F-S, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study [published online June 28, 2019]. Lancet Oncol. doi:https://doi.org/10.1016/S1470-2045(19)30272-4.
... to read the full story